News

Historic achievement: FDA approval of Abeona Therapeutics' ZEVASKYN accelerates momentum and expands treatment options for the EB community.
In a significant advancement for the Recessive Dystrophic Epidermolysis Bullosa (RDEB) community, the U.S. Food and Drug ...
Precision Medicine Online16m
FDA Approves Abeona's Zevaskyn, EC Authorizes Krystal's Vyjuvek for Rare Skin Disease
Both gene therapies were approved as treatments for dystrophic epidermolysis bullosa, a rare and debilitating genetic skin condition.
The American Journal of Managed Care39m
FDA Approves Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa
Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with ...
BioPharma Dive1h
Abeona cell therapy approved by FDA for rare skin condition
Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...
BioSpace2h
Abeona Gets FDA Nod for Rare Skin Disease Gene Therapy
The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.
Healio2h
FDA approves Zevaskyn for treatment of recessive dystrophic epidermolysis bullosa
The FDA has approved Zevaskyn for the treatment of recessive dystrophic epidermolysis bullosa, the company announced in a press release.With this approval, Zevaskyn (prademagene zamikeracel, Abeona) ...
Fierce Pharma3h
Abeona enters commercial gene therapy arena with FDA nod for Zevaskyn to treat rare genetic skin disease
Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).
US FDA approves first cell-based gene therapy for rare genetic skin disorder
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.
First Cell-Based Gene Therapy Approved for Rare Skin Disorder
The US Food and Drug Administration (FDA) has approved the first cell-based gene therapy for a rare genetic skin disorder.
US FDA approves Abeona's skin disorder therapy
The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday. Shares of the Cleveland-based drugmaker rose 13% in premarket trading. The gene ...
The Manila Times8h
DEBRA Research Announces Impact Investment into Nova Anchora to Advance Protein Therapy for Epidermolysis Bullosa
Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis ...